Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
ARTHEx Biotech
company
About
AntagomiR oligonucleotides to treat Myotonic Dystrophy patients.
- 1 - 10
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- €2.50M
- Industries
- Biotechnology
- Founded date
- Jan 1, 2019
- Number Of Employee
- 1 - 10
- Operating Status
- Active
ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successful development of our products.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
€2.50M
ARTHEx Biotech has raised a total of
€2.50M
in funding over 2 rounds. Their latest funding was raised on
Oct 14, 2022 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 14, 2022 | Grant | €2.50M | 1 |
European Innovation Council
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
ARTHEx Biotech is funded by 1 investors.
European Innovation Council
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
European Innovation Council
|
Yes | Grant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
